MaxWell Biosystems Company
MaxWell Biosystems is a company that provides solutions for basic neuroscience research and preclinical drug discovery. Their main product is MaxOne, an electrophysiology platform that records and stimulates electrogenic cells in vitro. MaxOne is a high-density microelectrode array that allows for single cell and network parameter extraction to facilitate phenotypic screening and drug toxicity/efficacy testing. MaxWell Biosystems was founded in 2016 as an ETH Z\xfcrich spin-off and provides instrumentation and solutions for research and development in neurosciences, stem cell and tissue engineering, ophthalmology, and other fields involving electrogenic cells.
Investors
Connections
Employee Number:
11-50
Estimated Revenue:
$10.8 Million
Industry:
Biotechnology